Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance - Hagens Berman

Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance - Hagens Berman

SAN FRANCISCO, Oct. 21, 2026 /PRNewswire/ -- Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class action lawsuit and upcoming November 3, 2026 lead plaintiff deadline under the Private Securities Litigation Reform Act (PSLRA).

Investors who suffered substantial losses purchasing Beta Bionics stock during the Class Period between July 30, 2025 and February 24, 2026, inclusive, are encouraged to submit your losses now to Hagens Berman to discuss their legal options.

CASE DETAILS & ACTION ITEM:

• Class Period: July 30, 2025 – Feb. 24, 2026
• Lead Plaintiff Deadline: Nov. 3, 2026
• Jurisdiction: U.S. District Court, Central District of California (Holtzman v. Beta Bionics, Inc., No. 26-cv-09999)
• Contact: BBNX@hbsslaw.com | 844-916-0895 | www.hbsslaw.com/bbnx
• Video: https://youtu.be/3mOFOZUJdAc

CASE SUMMARY & REGULATORY ALLEGATIONS

Beta Bionics is a medical device manufacturer focused on the commercialization of its flagship automated insulin delivery system, the iLet Bionic Pancreas.

The securities class action complaint alleges that throughout the Class Period, Beta Bionics and senior executives issued false and misleading statements regarding the safety, regulatory standing, and market adoption of the iLet system. Specifically, the complaint alleges that Defendants concealed:

1. Undisclosed FDA Form 483 Warnings: In June 2025, the FDA issued a Form 483 to Beta Bionics detailing over 18,000 unreported customer complaints regarding device functionality, algorithm failures, and severe hypoglycemia events.
2. Market Disclosures & Stock Drops: On January 8, 2026, Beta Bionics reported new patient starts missed analyst expectations, causing shares to fall 37%. Subsequently, on February 24, 2026, the FDA publicly released its formal Warning Letter detailing systemic reporting failures, triggering further steep price declines.

"We are investigating whether Beta Bionics management concealed critical FDA compliance issues and device safety warnings while promoting the commercial growth of the iLet Bionic Pancreas," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Beta Bionics and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding Beta Bionics should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email BBNX@hbsslaw.com.

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View original content to download multimedia:https://www.prnewswire.com/news-releases/beta-bionics-nasdaq-bbnx-faces-securities-fraud-class-action-amid-ilet-fda-compliance--hagens-berman-302915630.html

SOURCE Hagens Berman Sobol Shapiro LLP